Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients
| Autor: | Chiara Cremolini, Daniele Rossini, Paolo Alessandroni, Vittorina Zagonel, Paolo Giordani, Francesca Bergamo, Rodolfo Mattioli, Rossana Intini, Sara Lonardi, Daniele Santini, Francesca Negri, Vincenzo Catalano, Bruno Vincenzi, D. Sarti, Alfredo Falcone, Beatrice Borelli, Francesco Graziano, Silvia Stragliotto, Marco B. L. Rocchi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Cancer Research Organoplatinum Compounds Colorectal cancer Leucovorin Mucinous histology Gastroenterology 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols 80 and over Mucinous Aged 80 and over FOLFOXIRI Metastatic colorectal cancer Hazard ratio General Medicine Middle Aged Prognosis Adenocarcinoma Mucinous Oxaliplatin Bevacizumab Oncology 030220 oncology & carcinogenesis Adenocarcinoma Female Fluorouracil Colorectal Neoplasms medicine.drug Adult medicine.medical_specialty Irinotecan Chemotherapy 03 medical and health sciences Internal medicine medicine Humans Aged Camptothecin Retrospective Studies business.industry Proportional hazards model medicine.disease digestive system diseases 030104 developmental biology business |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 146:493-501 |
| ISSN: | 1432-1335 0171-5216 |
| DOI: | 10.1007/s00432-019-03077-w |
| Popis: | In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis. We investigated whether bevacizumab combined with different chemotherapy regimens may have an impact on clinical outcomes of MCRC patients with mucinous histology. 685 MCRC patients were classified in mucinous adenocarcinoma (MC) and non-mucinous adenocarcinoma (NMC) and were treated with first-line bevacizumab plus fluoropyrimidine (FP)-based, oxaliplatin (OXA)-based, irinotecan (IRI)-based, or FOLFOXIRI. Ninety-four (13.7%) patients had MC. With a median follow-up of 50 months, MC patients had a median overall survival (OS) of 28.2 months compared with 27.7 months for the NMC group [hazard ratio (HR) = 0.92; 95% confidence interval (CI) 0.70–1.19, P = 0.530]. The overall response rates for MC and NMC were 41.5% (95% CI 31.5–51.4) and 62.4% (95% CI 58.4–66.3), respectively (Chi-square test, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink